Lysogene SAS (LYS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Lysogene SAS (LYS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH366931D
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Lysogene SAS (Lysogene) is a clinical research center that offers basic research and clinical development programs. The center offers clinical development of gene therapy for neurodegenerative disorders such as Parkinson and Alzheimer diseases. It also develops models in gene therapy trials for rare pediatric diseases. Lysogene holds expertise in pre-clinical efficacy, gene therapy, toxicology and bio-distribution studies in small and large animal models. The center also develops models and standards to find novel solutions in setting up gene therapy trials for rare pediatric diseases. It has partnership with academic institutions for its research activities. Lysogene is headquartered in Paris, France.

Lysogene SAS (LYS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Lysogene SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Lysogene SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Lysogene SAS, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Lysogene Raises USD22.6 Million in Series A Financing 11

Partnerships 12

Lysogene Enters into Agreement with Institute of Genetics and Molecular and Cellular Biology (IGBMC) and SATT Conectus 12

Alcyone Lifesciences Enters into Agreement with Lysogene 13

Lysogene Enters into Agreement with University of Massachusetts Medical School and Auburn University 14

Licensing Agreements 15

Sarepta Therapeutics Enters into License Agreement with Lysogene 15

ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 16

Equity Offering 17

Lysogene Raises USD24.3 Million in IPO 17

Lysogene SAS-Key Competitors 18

Lysogene SAS-Key Employees 19

Lysogene SAS-Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Financial Announcements 21

Apr 16, 2018: Lysogene Reports First Quarter Financial Results and Provides Business Update 21

Mar 26, 2018: Lysogene: 2017 annual results 22

Jan 15, 2018: Lysogene Reports Fourth Quarter 2017 Financial Information 24

Oct 16, 2017: Lysogene: Financial Information for the Third Quarter of 2017 25

Sep 19, 2017: Lysogene Announces First Half 2017 Financial Results and Business Update 26

Jul 12, 2017: Lysogene: Financial Information for the Second Quarter of 2017 28

Apr 21, 2017: Lysogene: 2016 annual results 29

Apr 12, 2017: Lysogene: financial information for the 1st quarter of 2017 30

Corporate Communications 31

Sep 13, 2018: Lysogene announces changes in the composition of its Board of Directors 31

May 15, 2018: Lysogene Nominates Dr Ralph Laufer As Chief Scientific Officer And Member Of Executive Team 32

Apr 23, 2018: Lysogene Strengthens Board of Directors with Appointment of Dr. Peter Lichtlen 33

Sep 12, 2017: Lysogene Launches World Class Clinical Advisory Board 34

May 16, 2017: Lysogene Reinforces Its Management Team With the Nomination of Philippe Mendels-flandre as Chief Operating Officer 35

Product News 36

10/05/2017: Lysogene to Host Key Opinion Leader Meeting on Gene Therapy for Patients with Sanfilippo Syndrome Type A in New York City 36

Sep 21, 2017: Lysogene Holds First Parent Advisory Board in MPS IIIA 37

08/01/2018: Lysogene announces upcoming presentations at the 2018 international MPS symposium 38

03/28/2017: Lysogene Announces Baseline Data From First International Pivotal Observational Study In MPS IIIA 39

02/01/2018: Lysogene to Present Five Year Clinical Data in MPS IIIA at the 14th Annual WORLDSymposium 40

Product Approvals 41

Feb 06, 2018: Lysogene gets PIP Green Light from European Medicines Agency on MPS IIIA Pivotal Study; Paving Way for Clinical Trial Application Approvals 41

Feb 21, 2017: Lysogene Receives Orphan Drug Designation from EMA for LYS-GM101 for Treatment of GM1 Gangliosidosis 42

Feb 02, 2017: Lysogene Receives Orphan Drug Designation from FDA for LYS-GM101 for treatment of GM1 Gangliosidosis 43

Jan 18, 2017: Lysogene Receives Rare Pediatric Disease Designation from FDA for LYS-GM101 for Treatment of GM1 Gangliosidosis 44

Clinical Trials 45

May 30, 2017: Lysogene Completes Enrollment in First International Pivotal Observational Study in MPS IIIA 45

Other Significant Developments 46

Jul 23, 2018: Lysogene reports second quarter cash position and provides business and strategic update 46

Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48

List of Figures

Lysogene SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Lysogene SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Lysogene SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Lysogene SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Lysogene SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Lysogene SAS, Deals By Therapy Area, 2012 to YTD 2018 9

Lysogene SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Lysogene Raises USD22.6 Million in Series A Financing 11

Lysogene Enters into Agreement with Institute of Genetics and Molecular and Cellular Biology (IGBMC) and SATT Conectus 12

Alcyone Lifesciences Enters into Agreement with Lysogene 13

Lysogene Enters into Agreement with University of Massachusetts Medical School and Auburn University 14

Sarepta Therapeutics Enters into License Agreement with Lysogene 15

ReGenX Biosciences Enters Into Licensing Agreement With Lysogene 16

Lysogene Raises USD24.3 Million in IPO 17

Lysogene SAS, Key Competitors 18

Lysogene SAS, Key Employees 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Lysogene SAS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17833
Site License
USD 500 INR 35665
Corporate User License
USD 750 INR 53498

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com